Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2016 Sep 10;34(26):3189-94.
doi: 10.1200/JCO.2015.66.1140. Epub 2016 Jul 11.

Association of Chromosome 1q Gain With Inferior Survival in Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group

Eric J Gratias  1 , Jeffrey S Dome  1 , Lawrence J Jennings  1 , Yueh-Yun Chi  1 , Jing Tian  1 , James Anderson  1 , Paul Grundy  1 , Elizabeth A Mullen  1 , James I Geller  1 , Conrad V Fernandez  1 , Elizabeth J Perlman  2
Affiliations
Multicenter Study

Association of Chromosome 1q Gain With Inferior Survival in Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group

Eric J Gratias et al. J Clin Oncol. .

Abstract

Purpose: The goal of this study was to analyze the association of copy number gain of 1q in favorable-histology Wilms tumors (FHWTs) with event-free survival (EFS) and overall survival (OS) within each tumor stage and with 1p and 16q copy number loss and/or loss of heterozygosity.

Methods: Unilateral FHWTs from 1,114 patients enrolled in National Wilms Tumor Study-5 that were informative for 1p and 16q microsatellite markers (previously determined) and informative for 1q gain, 1p loss, and 16q loss using multiplex ligation-dependent probe amplification were analyzed.

Results: Eight-year EFS was 86% (95% CI, 84% to 88%) for the entire cohort. Of 1,114 patients, 317 tumors (28%) displayed 1q gain. Eight-year EFS was 77% for those with 1q gain and 90% for those lacking 1q gain (P < .001). Eight-year OS was 88% for those with 1q gain and 96% for those lacking 1q gain (P < .001). Within each disease stage, 1q gain was associated with inferior EFS (stage I, 85% v 95%; P = .0052; stage II, 81% v 87%; P = .0775; stage III, 79% v 89%; P = .01; stage IV, 64% v 91%; P = .001). OS was significantly inferior in patients with stage I (P < .0015) and stage IV disease (P = .011). With multivariable analysis, 1q gain was associated with an increased relative risk of relapse of 2.4 (P < .001), whereas 1p loss was not, despite significance on univariable analysis.

Conclusion: Gain of 1q is associated with inferior survival in unilateral FHWTs and may be used to guide risk stratification in future studies.

PubMed Disclaimer

Conflict of interest statement

Authors’ disclosures of potential conflicts of interest are found in the article online at www.jco.org. Author contributions are found at the end of this article.

Figures

Fig 1.
Fig 1.
Event-free survival (EFS) stratified for 1q gain.
Fig 2.
Fig 2.
Overall survival (OS) stratified for 1q gain.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

  • Update on Wilms tumor.
    Aldrink JH, Heaton TE, Dasgupta R, Lautz TB, Malek MM, Abdessalam SF, Weil BR, Rhee DS, Baertschiger R, Ehrlich PF; American Pediatric Surgical Association Cancer Committee. Aldrink JH, et al. J Pediatr Surg. 2019 Mar;54(3):390-397. doi: 10.1016/j.jpedsurg.2018.09.005. Epub 2018 Sep 19. J Pediatr Surg. 2019. PMID: 30270120 Free PMC article. Review.
  • Targeting TRIP13 in favorable histology Wilms tumor with nuclear export inhibitors synergizes with doxorubicin.
    Mittal K, Cooper GW, Lee BP, Su Y, Skinner KT, Shim J, Jonus HC, Kim WJ, Doshi M, Almanza D, Kynnap BD, Christie AL, Yang X, Cowley GS, Leeper BA, Morton CL, Dwivedi B, Lawrence T, Rupji M, Keskula P, Meyer S, Clinton CM, Bhasin M, Crompton BD, Tseng YY, Boehm JS, Ligon KL, Root DE, Murphy AJ, Weinstock DM, Gokhale PC, Spangle JM, Rivera MN, Mullen EA, Stegmaier K, Goldsmith KC, Hahn WC, Hong AL. Mittal K, et al. Commun Biol. 2024 Apr 8;7(1):426. doi: 10.1038/s42003-024-06140-6. Commun Biol. 2024. PMID: 38589567 Free PMC article.
  • A Children's Oncology Group and TARGET initiative exploring the genetic landscape of Wilms tumor.
    Gadd S, Huff V, Walz AL, Ooms AHAG, Armstrong AE, Gerhard DS, Smith MA, Guidry Auvil JM, Meerzaman D, Chen QR, Hsu CH, Yan C, Nguyen C, Hu Y, Hermida LC, Davidsen T, Gesuwan P, Ma Y, Zong Z, Mungall AJ, Moore RA, Marra MA, Dome JS, Mullighan CG, Ma J, Wheeler DA, Hampton OA, Ross N, Gastier-Foster JM, Arold ST, Perlman EJ. Gadd S, et al. Nat Genet. 2017 Oct;49(10):1487-1494. doi: 10.1038/ng.3940. Epub 2017 Aug 21. Nat Genet. 2017. PMID: 28825729 Free PMC article.
  • Gene Expression Analysis of (Paired) Primary and Relapsed Wilms Tumor Samples to Unravel the Underlying Factors Driving Tumor Recurrence.
    Groenendijk A, Drost J, Mavinkurve-Groothuis AMC, van Grotel M, Janssens GO, Littooij AS, van der Steeg AFW, van den Heuvel-Eibrink MM, Kester L, de Krijger RR. Groenendijk A, et al. Cancer Med. 2025 Jun;14(11):e70969. doi: 10.1002/cam4.70969. Cancer Med. 2025. PMID: 40439002 Free PMC article.
  • Nephroblastoma in Older Adult: Case Report and Review of Literature.
    Fernández-Ferreira R, Torres-Zazueta JM, Martínez-Medrano C, Meléndez-Mendoza A, Tavares-García S, Muñoz Rubiano MA, Portela-Rubio G, Robles-Castro J, Robles-Aviña JA, Ruiz Morales JM. Fernández-Ferreira R, et al. Case Rep Oncol. 2024 Jul 30;17(1):818-830. doi: 10.1159/000540279. eCollection 2024 Jan-Dec. Case Rep Oncol. 2024. PMID: 39144242 Free PMC article.
See all "Cited by" articles

References

    1. Termuhlen AM, Tersak JM, Liu Q, et al. Twenty-five year follow-up of childhood Wilms tumor: A report from the Childhood Cancer Survivor Study. Pediatr Blood Cancer. 2011;57:1210–1216. - PMC - PubMed
    1. Dome JS, Perlman EJ, Graf N. Risk stratification for Wilms tumor: Current approach and future directions. Am Soc Clin Oncol Ed Book. 2014:215–223. - PubMed
    1. Grundy PE, Telzerow PE, Breslow N, et al. Loss of heterozygosity for chromosomes 16q and 1p in Wilms’ tumors predicts an adverse outcome. Cancer Res. 1994;54:2331–2333. - PubMed
    1. Grundy RG, Pritchard J, Scambler P, et al. Loss of heterozygosity on chromosome 16 in sporadic Wilms’ tumour. Br J Cancer. 1998;78:1181–1187. - PMC - PubMed
    1. Klamt B, Schulze M, Thäte C, et al. Allele loss in Wilms tumors of chromosome arms 11q, 16q, and 22q correlate with clinicopathological parameters. Genes Chromosomes Cancer. 1998;22:287–294. - PubMed

Publication types

MeSH terms

Substances